Item Details

title

DEVELOPMENT OF A CELL THERAPY FOR HEMOPHILIA A

author

Trevisan, Brady Matthew

abstract

BACKGROUND: Hemophilia A (HA) is an X-linked genetic disorder that is characterized by a lack of functional factor VIII (FVIII) protein. The current treatment for hemophilia consists of the prophylactic injection of recombinant or plasma-derived FVIII every two to three days, and when a bleeding event occurs, to provide sufficient protein for blood to clot. However, up to 30% of patients who receive this treatment develop inhibitory antibodies to FVIII that prevent the protein from functioning.

subject

Cell and Gene Therapy

Factor VIII

FVIII Inhibitors

Hemophilia A

Microfluidics

von Willebrand Factor

contributor

Almeida-Porada, Graca (committee chair)

Doering, Christopher B (committee member)

Murphy, Sean V (committee member)

Chappell, John C (committee member)

date

2022-09-17T08:35:54Z (accessioned)

2024-09-16T08:30:07Z (available)

2022 (issued)

degree

Biomedical Engineering (discipline)

embargo

2024-09-16 (terms)

identifier

http://hdl.handle.net/10339/101266 (uri)

language

en (iso)

publisher

Wake Forest University

type

Dissertation